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Background: Anti-tumour necrosis factor (anti-TNF) therapies are an important recent development in the treatment
of autoimmune disease. Despite important side effects relating to immune suppression, there is lack of research into
patient experiences, attitudes and expectations about the information they receive prior to starting anti-TNF therapy.
Methods: In May 2011 participants were purposively sampled to form two focus groups varying in age, anti-TNF agent
and pre-therapy disease activity. A semi-structured topic guide was used to explore patients’ experiences regarding the
information they received prior to commencing anti-TNF therapy. The focus groups were
audio-taped and transcribed verbatim. Data were analysed using content analysis.
Results: Four key themes were identified.
Firstly, weighing the risks and benefits of anti-TNF therapy. However, most participants attached limited importance to
side effects, saying their strong desire for RA symptom control was overriding. Two reported deliberately concealing
illness in order to continue their medication.
Secondly, the desire for information. They suggested that counselling should occur at an early stage and not during a
severe RA flare-up.
Thirdly, the process of starting anti-TNF. Many identified that their biggest worry was whether they would be eligible
for the new medication. They remembered little about the investigations they underwent, and none said they would
have objected to being tested for blood borne viruses.
Finally, the experience of being on anti-TNF. Most were positive, describing effects on quality of life as well as symptoms.
Conclusions: The use of qualitative methodology in this study has enabled an understanding of patients’ attitudes
towards receiving information about anti-TNF therapy. The results may be useful to health professionals in terms of the
timing and content of the information given to patients prior to commencing anti-TNF therapy.
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Table 1 Focus group topic guide
1 How did you feel about starting anti-TNF?
2 What information do you remember being given before starting
anti-TNF?
3 How did you feel about the information you were given?
4 Did you do any of your own research around the time of starting
the medication?
5 Was there any additional information that you would have liked
to receive?
6 Were you aware of any additional tests/investigations that were
carried out before starting anti-TNF?
7 When would you contact the nurse about your treatment?
8 What is your understanding about having vaccinations whilst
on anti-TNF?
9 Were you given any information about any potential risks of
commencing anti-TNF?
10 How did you feel about the potential risks associated with anti-TNF?
11 Were you given information about the reasons why you might have
to stop your anti-TNF?
12 Are you aware of the various cancer screening programs in the UK?
13 Are you aware of the need to engage in cancer screening
programs?
14 As we learn more about anti-TNF therapy it seems it might be
sensible to screen patients for certain viruses such as hepatitis
and HIV. How would you feel if you needed to be tested for
these viruses?
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Anti-tumour necrosis factor therapies (anti-TNFs) are an
important recent development in the management of many
autoimmune diseases, the first of which was licensed for
rheumatoid arthritis (RA) by the European Medicines
Agency in 1999 [1]. With approximately 12,000 new cases
of RA per year in the UK, the number of people going on
to receive anti-TNF is increasing [2,3]. These medications
have potentially serious adverse effects which largely relate
to immune system suppression. For example, those on
anti-TNF are at significantly higher risk of serious infection,
and there is a theoretical increase in the risk of cancer [4].
Potential anti-TNF side effects can influence individuals’
eligibility or desire to start treatment. The importance of
effective patient education regarding RA and the potential
benefits and risks of treatment is therefore acknowledged
as important by many authors, and is a recognised way of
improving patient concordance and adherance [5]. The
British Society of Rheumatology (BSR) emphasise the im-
portance of ongoing patient education, empowerment and
self-management in RA [6,7], and NICE highlight the im-
portance of informed decision making in RA [8].
While there has been much work relating to patient
preferences towards receiving general information and
their involvement in clinical decision making, there is
little that relates directly to anti-TNF therapy [9-12]. We
therefore aimed to gain understanding of patient experi-
ences of starting anti-TNF medication, and explore their
attitudes and expectations towards the information they
received during this process.
Methods
The study was carried out in the Haywood Rheumatol-
ogy Centre (HRC) in North Staffordshire UK, which
serves a population of over 500,000 patients. At the time
of recruitment over 2500 patients with RA were under
the care of a team of 10 consultant rheumatologists and
3 nurse consultants. Two hundred and fifty of these pa-
tients were taking anti-TNF. In this unit, pre-therapy
counselling for anti-TNF is undertaken by a specialist
nurse who explains the purpose of treatment, how it
works, and the important side-effects. Patients are asked
screening questions about present and past cancer, and
are screened for tuberculosis (Tuberculin sensitivity skin
test and chest XRay) and Hepatitis B (blood test). An
Arthritis Research UK leaflet is provided.
Twenty participants were purposively sampled from
the existing list of RA patients at the hospital to give a
spectrum of patient age, disease duration, pre anti-TNF
disease activity and anti-TNF agent received. They were
approached during routine clinic appointments and
received an invitation letter accompanied by patient
information leaflet which explained the study aims and
methods. Ethical approval was obtained from NorthStaffordshire and South Staffordshire Local Research
Ethics Committees. Written consent was obtained from
all participants according to the Declaration of Helsinki.
In May 2011 two facilitated focus groups (one male and
one female) took place in a conference room at HRC.
These lasted 108 and 94 minutes duration respectively..
Gender specific groups were chosen in order to reduce any
potential embarrassment whilst patients discussed topics
such as sexually acquired infections (i.e. HIV) and gender
specific cancers (i.e. prostate) and associated cancer screen-
ing. An introductory talk was delivered by the focus group
facilitator (PA), which emphasised anonymity and confi-
dentiality. Participants were asked open questions about
their personal experience of starting anti-TNF and the
information they received during this process, and whether
they thought any aspect of patient care could have been
improved. A topic guide (see Table 1) was developed from
a literature review and discussion with a patient partner
and health professionals, however participants were en-
couraged to speak freely and openly about their thoughts
and feelings. The topics of cancer screening and HIV test-
ing were included as it was felt that data in this area were
particularly lacking. The question “how would you feel if
you needed to be tested for HIV” was deliberately asked in
both focus groups.
The discussions were audio-taped, and written notes
were taken to collect non-verbal cues. Recordings were
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donyms were used and other identifying information
was removed.
Data analysis used content analysis combined with
Colazzi’s procedural steps [13]. Whereas content analysis
involved identifying recurring words and themes from the
focus group data. The addition of Colazzi’s procedural
steps provided a framework which enabled the researchers
to move beyond the stage of solely identifying the themes
to exploring the meaning (and its significance) relating
to the themes. This approach increased the researchers un-
derstanding of the experience and information needs of pa-
tients taking anti-TNF therapy. Analysis was undertakenby
two members of the study team. Each identified areas of
concordance and discordance in the data, and through
discussion, a set of key themes were then identified. To
validate the analysis [13], written summaries of focus
groups and the themes identified were provided to all
participants, who were given the opportunity to respond
with comments. None wished to add further comment
to the findings.
Results
Out of the 10 men and 10 women who were invited, five
of each agreed to take part. Those that declined to par-
ticipate were unable to attend focus groups on pre-
determined dates. Characteristics of the participants are
shown in Table 2.
The following four themes were identified:
1) The risks and benefits of taking anti-TNF
2) Desires for information about anti-TNF
3) The process of starting anti-TNF
4) The experience of being on anti-TNF
1) The risks and benefits of taking anti-TNFTable 2 Participant characteristics




Robert 85 21 Etanercept
Steve 47 17 Etanercept
Jim 57 18 Etanercept
Bob 79 21 Adalimumab
Terry 46 11 Adalimumab
Female group:
Katherine 64 5 Adalimumab
Helen 62 10 Adalimumab
Val 64 26 Adalimumab
Claire 63 15 Etanercept
Sally 67 21 EtanerceptPrior to treatment initiation, participants recalled be-
ing excited about the prospect of taking anti-TNF.
Nevertheless, some said they had apprehensions about
starting a new medication, and this often related to
problems they had experienced with previous treat-
ments. Perceived increased risk of cancer was also com-
monly identified as a concern.
“Oh yes I was worried about cancer. I mean I still am
really.” – Sally
“I thought ‘increased risk of tumours’, and it really
crossed my mind and I gave it a lot of thought.” – Val
“I think it’s the one that sticks in your mind [cancer].”
– Helen
However, when asked about cancer screening in the
UK, nobody identified this as particularly important for
themselves because they take anti-TNF. Some admitted
not attending screening appointments. Although there
was concern about infection risk, this was not perceived
as important as cancer risk:
“ Infections… oh no because I think you normally
fight those off. You know as long as you are basically
healthy I just presume that you can fight those off.
But cancer of course is a different thing.” - Sally
Many recalled that becoming ill with an infection
meant they’d had to stop taking anti-TNF. They were
often more worried about this than the infection itself:
“I just don’t want to not take the drug. I put up with
it and hope it goes.” – Steve
“I’ve just had a chest infection…I don’t know if it’s the
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They felt this way about other side effects as well, in-
cluding cancer:
“I wasn’t worried about having the cancer because
I thought this is something else that’s come along
that I have to deal with, but in the back of my
mind I thought ‘at my age now, if I’d got to come
off [anti-TNF] for 5 years, I’d never go back
onto it’. That really worried me.” – Val
Two women admitted trying to conceal infections in
order to continue receiving their medication:
“I was trying not to sneeze or sniff or anything, or
cough. Definitely don’t cough!” – Katharine
“Yes, definitely don’t cough! [in agreement with
Katherine]” – Helen
Despite acknowledging the importance of side effects,
most participants described the severity of their rheuma-
toid disease when making the decision about anti-TNF.
Many explained that the prospect of symptom control was
more important than any fears about drug side effects.
“When you’re that ill, if somebody told me to eat mud
or clay and it might help [I would].” – Steve
“You’re scared of rheumatoid arthritis. That’s the
thing you’re scared of the most… you’re scared of
the pain, what it does to your joints, you know,
you’re already scared. So information can’t scare
you… If I’m going to get cancer, I’m going to get
cancer. It can’t be any worse than rheumatoid
arthritis.” - Tom
“It could give me two heads and I’d still try it.” – Helen
Many participants expressed their trust in the rheuma-
tology team, and explained that this was why they didn’t
worry about side effects.
“[Named rheumatology nurse and doctor], they’re like
God to me. What they say goes! You know, I feel, I’ve
got a lot of confidence in them. I feel like I trust them
with my life.” - Val
“What I like is that she’s at the end of the phone …
you know, if we were worried we could always get
hold of her.” - Helen
2) Desires for information about anti-TNF
Participants reported getting information about anti-
TNF from many different sources. Some actively sought
information by doing research, while others were morepassive. With regards to the quantity of information they
wanted, opinions differed widely. Unsurprisingly, the few
who had researched anti-TNF extensively also said they
expected to be provided with very detailed information.
Some talked about the danger of being given too much
information:
“I can’t take it all on board when you’re telling me
something. You know, I’ll get home and think ‘oh,
what did she say then?’” - Sally
“I was quite happy with the information I got…I don’t
think reams off the internet would have made any
difference to me.” – Claire
“I feel as though I was quite well informed, but not
overly bombarded with information.” – Christopher
Participants said they were often given information about
anti-TNF while they were having a severe flare-up of their
arthritis. Many felt that this was not a good time to receive
information, and described how the activity of their
rheumatoid arthritis affected the way they interpreted
information:
“I was in such a hell of a state up on the ward they
could have said anything to me and it would have
probably gone in one ear and out the other. Because,
as I said, I was really bad.” – Peter
“If you’re given a leaflet when you’re feeling that bad
you just go ‘oh yeah I’ll read that later’. I mean you
don’t even watch television, don’t want to read
something.” – Steve
“You just focus up on that cancer, prostate cancer or
whatever, just because of the mood you’re in. So
sometimes you might not be in the best place to make
a rational decision.” – Christopher
“When you’re really ill … you perhaps can’t make
decisions as well.” – Val
There was general consensus that it would be benefi-
cial to provide patients with information about anti-TNF
at an earlier stage:
“It might be a good idea to get people with
rheumatoid arthritis, whatever state you’re in, to start
to become aware of the drugs that are available as the
years go by.” – Val
“I didn’t know anything about anti-TNF. I’d gone
through [many] different drugs … it would have
been nice to know that there was something
else.” – Sally
When considering counselling for anti-TNF as a
whole, most participants recognised that it would be dif-
ficult to make recommendations that suited everybody.
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Some participants admitted that their biggest worry
was becoming eligible for anti-TNF, rather than the side
effects:
“I just focussed on whether I could get through the
hoops to actually being given the drug. When I was
told ‘you pass all the criteria’, then I started thinking
‘well maybe it could cause problems’.” – Steve
“I think I became a bit of a pest in the end, you know.
That was my first question before I sat down: ‘can I
go on Humira yet?’” – Katharine
Participants remembered little about the investigations
they underwent before starting anti-TNF. Most were
aware they had some blood tests but weren’t sure what
for, and some remembered being tested for tuberculosis.
When exploring views on being tested for blood borne
viruses including HIV, participants were open-minded
about the idea:
“Well one would assume that would have been carried
out automatically! [laughs]” – Peter
“So you think people wouldn’t want to have the test?
… I wouldn’t mind it.” – Steve
“I can’t see why people would object to having a test
for that – it’s for their own benefit isn’t it really.” - Val
One woman explained that her views would depend
how a test was offered:
“I think if it was a general one, you know, if you
were tested for this, this, this and this, and HIV was
one of them. If it was something that happened to
everybody, nobody could say ‘I’ve been picked on’
because it would be a standard thing. It would
just be something else that you were tested
for.” – Katharine4) The experience of being on anti-TNF
When considering the overall effect of being on anti-
TNF, participants were generally very positive. Many de-
scribed a dramatic change in their physical symptoms,
and some explained how they thought this had improved
their quality of life:
“Outsiders, family, doesn’t matter who it is, you can’t
explain the feelings and the pain you know. So for me,
it’s been a godsend.” – Tom
“Well it’s changed my life. I mean I was brought in, I
couldn’t walk. I couldn’t do anything. I lead a normal
life now; it’s a miracle to me.” – Helen“I’ve been tons better. I don’t really think I’m the
same person I was at the beginning… I’m very happy
at the moment.” – Sally
“It’s been really good the results and I’ve had no
problems as far as I can tell.” – Claire
“I’ve got a good quality of life now.”- Katherine
Discussion
The use of qualitative methodology in this study has en-
abled an understanding of patients’ experiences, atti-
tudes and expectations towards receiving information
about anti-TNF medication. Apprehensions about cancer
were common, and many considered themselves at on-
going risk while they were taking anti-TNF. Interestingly,
however, participants did not consider engagement in
national cancer screening programmes as particularly
important for themselves. Participants were aware of an
increased risk of infection, however they were less
concerned about this than cancer-risk. Most said that
they considered potential drug side effects when decid-
ing to start anti-TNF. Many, however, emphasised a far
greater importance of wanting to control their RA symp-
toms, and very few considered declining anti-TNF. In
addition, many reported that their main fear about side
effects was that those side effects would result in a dis-
continuation of anti-TNF. Desire for information about
anti-TNF varied widely, and many participants identified
the need for a balance between knowing too much and
too little. Many participants stated that the best time to
receive information was when their RA was not actively
flaring, and that it may have been useful to be given in-
formation earlier in their treatment course. Participants
had anxieties relating to the process of becoming eligible
for anti-TNF, and remembered hoping they would qualify.
Knowledge of tests done prior to starting was generally
low, and participants were open-minded about being
tested for blood borne viruses including HIV.
Many authors have described how patients weigh the
potential risks and benefits of different treatments, and
then make a decision [11,14]. Research involving rheuma-
tology patients has often identified the prospect of symp-
tom control as an important factor in a treatment
decisions, and this is reflected in the present work [15,16].
In their work on patient attitudes towards anti-TNF, Mar-
shall et al. describe how some patients were desperate to
try new treatments [15], and Sanderson et al. describe a
key theme of patients ‘willing to try anything’ [16].
There has been much work into patient attitudes to-
wards information provision, and how this relates to
their preferences for involvement in decision making
[17,18]. In a study into decision making among women
with RA, at the important phase of ‘knowledge acquisi-
tion’, patients want ‘ample information about the medi-
cation presented in a straightforward way’ [11]. This
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to reduce their anxiety, and is supported by other re-
search on interpretation of reassurance in rheumatology
clinics [19]. It is often suggested that patients who are
involved in decisions about their care are more likely to
comply with medication [5-7]. However, in a study of
secondary care patients, 80% of patients tend to choose
a ‘collaborative’ or ‘passive’ (rather than ‘active’) role in
decision making [9]. A study on living with arthritis de-
scribes a spectrum of patient preference between taking
charge and not taking charge [20]. Our findings are in
accordance with this theory, with many patients wanting
only a limited amount of information. Passive decision
making seemed also to be associated with trust in
healthcare professionals. In their work into perspectives of
patients on COBRA combination therapy in RA, Tuyl
et al. identify the importance of ‘trust in [one’s] physician.
This ‘reciprocal trust’, is an important theme in a study on
the doctor patient relationship in rheumatic disease [17].
We are unaware of any previous work looking into RA
patients’ preferences for the time at which they receive
information regarding anti-TNF therapy. Although the
most convenient and common time for this to occur in
the patient pathway is when they become eligible for
anti-TNF, data from this study suggest this might not be
the most effective nor desirable time. At the time of
starting anti-TNF patients are usually unwell, and this
may have effects on their ability to receive, retain and
make judgements about information. It is possible that
they could benefit from gaining awareness of anti-TNF
at an earlier stage.
Rather than having apprehensions about starting anti-
TNF, many participants described their fear of stopping
the medication, which is in accordance with findings of
a previous study [16]. We are unaware of data presented
elsewhere which suggest patients may actively hide ill-
ness in order to remain on anti-TNF, and this an area
that would benefit from further research.
In 2004, a study identified patients’ anxieties relating
to assessment for eligibility for anti-TNF [15]. The
present study provides evidence that these still remain,
and suggests that, for some, they are more important
than drug side effects.
No previous studies have explored RA patient atti-
tudes towards being tested for blood borne viruses. The
majority of patients were not concerned by blood borne
virus testing, which is in accordance with recent work in
general practice and acute medical settings [21]. Partici-
pants in the present study, however, were likely to be at
low risk of blood borne viruses, and therefore more
work to include a patient group more likely to be ‘at risk’
may be worthwhile.
The present findings represent the experiences, atti-
tudes and perceptions of ten participants with RAregarding information provision prior to commencing
anti-TNF. While this sample size would routinely be
seen as adequate for this type of qualitative research, in-
corporating the opinions from a wider spectrum of
people may have generated more themes. All partici-
pants were under the care of a single rheumatology
centre, and experience of information received at other
sites may be different. All participants were successfully
established on anti-TNF therapy and the experience of
individuals who have discontinued the medication may
be different, potentially with less willingness to trade risk
of adverse reaction for potential symptomatic relief, and
a desire for more information about new medications.”
As participants had been taking anti-TNF for some con-
siderable time their experiences may be affected by recall
bias. It is possible they did not accurately recall the infor-
mation they received or what form it was in. Importantly
there was also potential for participants to confuse infor-
mation relating to anti-TNF with information from previ-
ous counselling sessions for other rheumatoid arthritis
medications over the years. However, the richness of the
data would suggest that the commencement of anti-TNF
was a major event for the participants and they could re-
call their attitudes and experiences with relative ease and
in-depth. Other sources of potential bias were reduced
through the involvement of a patient partner to inform
the development of the topic guide and the validation of
the data by two researchers and the participants.
Conclusion
The authors feel that this study provides important insight
into how some patients feel about starting anti-TNF ther-
apy and the information they receive during this process.
Findings may be useful to professionals throughout the
multidisciplinary team in guiding patient counselling about
these new medications. Further research is needed to valid-
ate our findings and expand on themes including fears
about stopping anti-TNF, the deliberate concealment of ill-
ness, preferences for timing of information, and attitudes
towards testing for blood borne viruses.
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